Great West Life Assurance Co. Can lifted its stake in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 5.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 101,971 shares of the biotechnology company’s stock after buying an additional 5,500 shares during the period. Great West Life Assurance Co. Can owned approximately 0.13% of Momenta Pharmaceuticals worth $1,937,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of MNTA. Aperio Group LLC lifted its stake in shares of Momenta Pharmaceuticals by 9.4% during the second quarter. Aperio Group LLC now owns 18,151 shares of the biotechnology company’s stock worth $307,000 after buying an additional 1,562 shares during the period. Municipal Employees Retirement System of Michigan lifted its stake in shares of Momenta Pharmaceuticals by 8.1% during the second quarter. Municipal Employees Retirement System of Michigan now owns 15,780 shares of the biotechnology company’s stock worth $267,000 after buying an additional 1,180 shares during the period. Texas Permanent School Fund lifted its stake in shares of Momenta Pharmaceuticals by 4.1% during the second quarter. Texas Permanent School Fund now owns 48,755 shares of the biotechnology company’s stock worth $824,000 after buying an additional 1,934 shares during the period. Pictet Asset Management Ltd. lifted its stake in shares of Momenta Pharmaceuticals by 4.6% during the second quarter. Pictet Asset Management Ltd. now owns 155,929 shares of the biotechnology company’s stock worth $2,261,000 after buying an additional 6,900 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Momenta Pharmaceuticals by 22.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 358,055 shares of the biotechnology company’s stock worth $6,052,000 after buying an additional 64,817 shares during the period. Institutional investors and hedge funds own 93.45% of the company’s stock.

Several equities research analysts have recently commented on the stock. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Cowen set a $15.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Robert W. Baird downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $22.00 to $15.00 in a research note on Friday, October 6th. Finally, ValuEngine downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating and nine have given a hold rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $15.00.

In related news, President Craig A. Wheeler sold 35,667 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the transaction, the president now directly owns 286,121 shares in the company, valued at $5,444,882.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elizabeth Stoner sold 5,500 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $13.10, for a total transaction of $72,050.00. Following the completion of the transaction, the director now owns 13,240 shares of the company’s stock, valued at approximately $173,444. The disclosure for this sale can be found here. Insiders have sold 49,506 shares of company stock valued at $861,419 over the last 90 days. 4.40% of the stock is currently owned by insiders.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at $13.60 on Monday. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. The company had revenue of $24.09 million during the quarter, compared to the consensus estimate of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The firm’s quarterly revenue was down 17.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.26) earnings per share. equities research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/great-west-life-assurance-co-can-boosts-stake-in-momenta-pharmaceuticals-inc-mnta/1770708.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.